Inhibrx Biosciences Inc ($INBX) has generated 5 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on July 25, 2025. Jacob Plieth (@jacobplieth) is the most-active voice discussing the biotech company, accounting for 4 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The discussion has centered on clinical development and safety data related to the company's pipeline programs.

Recent mentions have focused on clinical trial developments and safety monitoring. In November 2025, @jacobplieth discussed liver toxicity data from the Chondragon study presented at CTOS25, noting that a liver toxicity death occurred prior to implementation of new screening protocols. Most recently, on May 8, 2026, @adamfeuerstein highlighted that $INBX was reporting Phase 2 data for INBRX-106, an OX40 cancer drug that reportedly drew interest from Merck and other companies, with the data presentation scheduled for Monday.